5/22/2025
Last update
5/22/2025
Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 43 Researches
7.4
USERS' SCORE
Good
Based on 2 Reviews
8.5
Supplement Facts
Serving Size: 4 Capsules
Serving Per Container: 30
Amount Per Serving
%DV
Vitamin C (from culture of S. cerevisiae)
50 mg
56%
Vitamin D (as D3 from culture of S. cerevisiae)
40 mcg (1,600 IU)
200%
Vitamin K (from culture of S. cerevisiae)
120 mcg
100%
Calcium (naturally occurring from Algae)
1,100 mg
85%
Magnesium (from Algae and Dead Sea minerals)
357 mg
85%
Vitamin K (as K2 MK-7)
50 mcg
+
Strontium (naturally occurring from Algae)
3.8 mg
+
Boron (from Brown Rice Chelate)
3 mg
+
Silica (naturally occurring from Algae)
2.2 mg
+
Vanadium (naturally occurring from Algae)
25 mcg
+
Raw Probiotic & Enzyme BlendLipase, Protease, Aspergillopepsin, beta-Glucanase, Cellulase, Bromelain, Phytase, Lactase, Papain, Peptidase, Pectinase, Hemicellulase, Xylanase, [Lactobacillus bulgaricus, Lactobacillus plantarum] (500 Million CFU).
64 mg
+
Top Medical Research Studies
8
Magnesium scaffold shows promising results
We investigated the clinical safety and performance of a new magnesium scaffold known as DREAMS 3G. This innovative treatment aims to match the effectiveness of drug-eluting stents in coronary interventions.
Over one year, a total of 116 patients were monitored, showing promising results with minimal lumen loss and no adverse events like cardiac death or major thrombosis. Despite a few revascularization interventions, the scaffold appears to be a viable alternative.
Overall, our findings support its potential use in heart treatments.
Over one year, a total of 116 patients were monitored, showing promising results with minimal lumen loss and no adverse events like cardiac death or major thrombosis. Despite a few revascularization interventions, the scaffold appears to be a viable alternative.
Overall, our findings support its potential use in heart treatments.
Read More
9
Our research focused on understanding how Vitamin D (VitD) might influence blood clotting, especially in the context of COVID-19. We found that when human endothelial cells were exposed to IL-6—an inflammatory cytokine associated with severe COVID-19—it led to dysfunction in these cells. This dysfunction was marked by increased levels of Tissue Factor (TF) and cell adhesion molecules (CAMs), which promote blood clotting.
Remarkably, when we treated these endothelial cells with VitD, we observed a reversal of these harmful effects. VitD appeared to inhibit the expression of TF and CAMs and even modulated the levels of the ACE2 receptor, which is crucial for the entry of the virus into cells. Our findings suggest that VitD could play a protective role against the blood clotting complications associated with COVID-19 by counteracting IL-6's effects on endothelial cells.
Overall, this study paves the way for further research into VitD as a potential therapeutic option for mitigating thrombotic risks in COVID-19 patients.
Remarkably, when we treated these endothelial cells with VitD, we observed a reversal of these harmful effects. VitD appeared to inhibit the expression of TF and CAMs and even modulated the levels of the ACE2 receptor, which is crucial for the entry of the virus into cells. Our findings suggest that VitD could play a protective role against the blood clotting complications associated with COVID-19 by counteracting IL-6's effects on endothelial cells.
Overall, this study paves the way for further research into VitD as a potential therapeutic option for mitigating thrombotic risks in COVID-19 patients.
Read More
9
We investigated the effects of magnesium oxide nanoparticles, created using fruit extract, on blood clotting and oxidative stress. Our experiments showed that these nanoparticles significantly extended clotting time, indicating an anticoagulant effect. They also effectively reduced damage to red blood cells and various tissues in laboratory tests, helping to restore their function. Importantly, we found these nanoparticles non-toxic, suggesting they could be a promising treatment option for oxidative stress-related conditions without adverse side effects. However, further research is needed to fully understand their potential in clinical applications.
Read More
Most Useful Reviews
9
Eliminated back ache
14 people found this helpful
Raw Calcium has completely alleviated my low back ache during my monthly cycle, which I didn’t expect. My blood calcium levels have been low before, and unlike other calcium supplements, this one does not cause me chest pain. Initially, I was hesitant to try it, but I’m now thrilled I did, as it has made my monthly experience much more manageable by removing my back pain.
Read More
6
Good for vessels
The quality is excellent. While the effects are not immediate, it’s beneficial for blood vessels. This supplement is perfect, and you can consume the powder without the capsules.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 43 Researches
7.4
- All Researches
9
We explored the role of calcium in promoting blood coagulation using a new zeolite-embedded regenerated cellulose aerogel (Z-RCA). This innovative hemostatic agent was designed to minimize common issues seen with previous zeolite-based products, like heat-induced tissue damage and unwanted blood clotting elsewhere in the body.
Our results showed that this aerogel effectively absorbed blood while releasing calcium ions, which play a crucial role in the blood clotting process. By combining the properties of zeolite and the calcium-releasing ability of the aerogel, we found that Z-RCA not only facilitated quicker blood clotting but did so safely, with less risk of adverse effects.
In animal trials, we observed that Z-RCA stopped bleeding faster than existing options like Quikclot and notably reduced blood loss by over 62%. This combination of effectiveness and safety makes Z-RCA a promising solution for achieving efficient hemostasis during emergencies.
Our results showed that this aerogel effectively absorbed blood while releasing calcium ions, which play a crucial role in the blood clotting process. By combining the properties of zeolite and the calcium-releasing ability of the aerogel, we found that Z-RCA not only facilitated quicker blood clotting but did so safely, with less risk of adverse effects.
In animal trials, we observed that Z-RCA stopped bleeding faster than existing options like Quikclot and notably reduced blood loss by over 62%. This combination of effectiveness and safety makes Z-RCA a promising solution for achieving efficient hemostasis during emergencies.
Read More
9
Our research focused on understanding how Vitamin D (VitD) might influence blood clotting, especially in the context of COVID-19. We found that when human endothelial cells were exposed to IL-6—an inflammatory cytokine associated with severe COVID-19—it led to dysfunction in these cells. This dysfunction was marked by increased levels of Tissue Factor (TF) and cell adhesion molecules (CAMs), which promote blood clotting.
Remarkably, when we treated these endothelial cells with VitD, we observed a reversal of these harmful effects. VitD appeared to inhibit the expression of TF and CAMs and even modulated the levels of the ACE2 receptor, which is crucial for the entry of the virus into cells. Our findings suggest that VitD could play a protective role against the blood clotting complications associated with COVID-19 by counteracting IL-6's effects on endothelial cells.
Overall, this study paves the way for further research into VitD as a potential therapeutic option for mitigating thrombotic risks in COVID-19 patients.
Remarkably, when we treated these endothelial cells with VitD, we observed a reversal of these harmful effects. VitD appeared to inhibit the expression of TF and CAMs and even modulated the levels of the ACE2 receptor, which is crucial for the entry of the virus into cells. Our findings suggest that VitD could play a protective role against the blood clotting complications associated with COVID-19 by counteracting IL-6's effects on endothelial cells.
Overall, this study paves the way for further research into VitD as a potential therapeutic option for mitigating thrombotic risks in COVID-19 patients.
Read More
9
We investigated the effects of magnesium oxide nanoparticles, created using fruit extract, on blood clotting and oxidative stress. Our experiments showed that these nanoparticles significantly extended clotting time, indicating an anticoagulant effect. They also effectively reduced damage to red blood cells and various tissues in laboratory tests, helping to restore their function. Importantly, we found these nanoparticles non-toxic, suggesting they could be a promising treatment option for oxidative stress-related conditions without adverse side effects. However, further research is needed to fully understand their potential in clinical applications.
Read More
8
We explored the impact of different calcium infusions on clotting risks in neonates undergoing cardiac surgery. Our study involved analyzing data from 135 babies who received either calcium chloride or calcium gluconate during their treatment.
The findings highlighted a significant concern: when using calcium chloride, the incidence of thrombotic events was notably higher compared to those treated with calcium gluconate. Specifically, the odds of experiencing a blood clot were over three times greater in patients given calcium chloride.
With an overall thrombus occurrence of 9.9%, we observed that only 4.6% of the group receiving calcium gluconate developed such complications compared to 15% in the calcium chloride group. The evidence suggests that switching from calcium chloride to calcium gluconate could potentially reduce the risk of harmful blood clots in these vulnerable patients.
The findings highlighted a significant concern: when using calcium chloride, the incidence of thrombotic events was notably higher compared to those treated with calcium gluconate. Specifically, the odds of experiencing a blood clot were over three times greater in patients given calcium chloride.
With an overall thrombus occurrence of 9.9%, we observed that only 4.6% of the group receiving calcium gluconate developed such complications compared to 15% in the calcium chloride group. The evidence suggests that switching from calcium chloride to calcium gluconate could potentially reduce the risk of harmful blood clots in these vulnerable patients.
Read More
8
We set out to understand how levels of vitamin D, specifically serum 25-hydroxyvitamin D (25OHD), influence the risk of developing venous thromboembolism (VTE), which includes serious conditions like deep vein thrombosis and pulmonary embolism. To do this, we examined a large cohort of nearly 378,000 participants, all free from VTE at the start of the study.
Our analysis focused on the relationship between vitamin D levels and VTE risk, particularly in individuals with diabetes compared to those without. Over a median follow-up period of 12.5 years, we recorded just over 10,600 new cases of VTE.
The findings were quite revealing: higher serum 25OHD concentrations were associated with a lower risk of VTE. This inverse relationship was especially pronounced in participants with diabetes. Interestingly, while we assessed various genetic factors that could influence VTE risk, they did not significantly change how vitamin D affected the likelihood of developing a blood clot.
However, we did find that specific genetic variations in the vitamin D receptor appeared to enhance the protective effects of vitamin D against VTE. Overall, we are encouraged by our findings, which suggest that maintaining sufficient levels of vitamin D may help reduce the risk of blood clots, particularly in those already managing diabetes.
Our analysis focused on the relationship between vitamin D levels and VTE risk, particularly in individuals with diabetes compared to those without. Over a median follow-up period of 12.5 years, we recorded just over 10,600 new cases of VTE.
The findings were quite revealing: higher serum 25OHD concentrations were associated with a lower risk of VTE. This inverse relationship was especially pronounced in participants with diabetes. Interestingly, while we assessed various genetic factors that could influence VTE risk, they did not significantly change how vitamin D affected the likelihood of developing a blood clot.
However, we did find that specific genetic variations in the vitamin D receptor appeared to enhance the protective effects of vitamin D against VTE. Overall, we are encouraged by our findings, which suggest that maintaining sufficient levels of vitamin D may help reduce the risk of blood clots, particularly in those already managing diabetes.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
9
Eliminated back ache
14 people found this helpful
Raw Calcium has completely alleviated my low back ache during my monthly cycle, which I didn’t expect. My blood calcium levels have been low before, and unlike other calcium supplements, this one does not cause me chest pain. Initially, I was hesitant to try it, but I’m now thrilled I did, as it has made my monthly experience much more manageable by removing my back pain.
Read More
6
Good for vessels
The quality is excellent. While the effects are not immediate, it’s beneficial for blood vessels. This supplement is perfect, and you can consume the powder without the capsules.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Jin Z, Chen L, Liu X, Xia R, Li W, et al. Zeolite firmly anchored regenerated cellulose aerogel for efficient and biosafe hemostasis. Int J Biol Macromol. 2025;304:140743. 10.1016/j.ijbiomac.2025.140743
- Tran VA, Griffin EM, Elliott JD, Scholl RL, Hill RB, et al. Thrombotic Complications Associated With Right Atrial Lines in Neonates and Infants Undergoing Cardiac Surgery. Is Calcium Chloride a Culprit?. J Cardiothorac Vasc Anesth. 2025. 10.1053/j.jvca.2025.01.008
- Xiang H, Zhou C, Gan X, Huang Y, He P, et al. Relationship of Serum 25-Hydroxyvitamin D Concentrations, Diabetes, Vitamin D Receptor Gene Polymorphisms and Incident Venous Thromboembolism. Diabetes Metab Res Rev. 2025;41:e70014. 10.1002/dmrr.70014
- Rachman A, Iriani A, Irawan A, Juanputra S, Betsy R. Adequate serum 25-hydroxy-vitamin D levels are correlated with low anti-PF4 levels in mild COVID-19 Patients: An observational study. Medicine (Baltimore). 2024;103:e39252. 10.1097/MD.0000000000039252
- Wang R, Tian Z, Wang C, Zhang B, Zhu M, et al. 1,25-Dihydroxyvitamin D3 attenuates platelet aggregation potentiated by SARS-CoV-2 spike protein via inhibiting integrin αIIbβ3 outside-in signaling. Cell Biochem Funct. 2024;42:e4039. 10.1002/cbf.4039
- Andersen MK, Rüdiger IH, Vestergaard AL, Palarasah Y, Bor P, et al. Vitamin D Deficiency is Associated With Increased Plasminogen Activator Inhibitor 1/Plasminogen Activator Inhibitor 2 Ratio in Pregnancy. Clin Appl Thromb Hemost. 2023;29:10760296231201855. 10.1177/10760296231201855
- Şaylık F, Selçuk M, Akbulut T, Çınar T. The Association between Vitamin D Levels and Thrombus Burden in Patients with ST-Elevation Myocardial Infarction. J Tehran Heart Cent. 2022;17:48. 10.18502/jthc.v17i2.9835
- Uguz B, Oztas S, Zengin I, Topal D, Tiryakioglu SK, et al. Relationship between vitamin D deficiency and thrombus load in patients with ST-elevation myocardial infarction. Eur Rev Med Pharmacol Sci. 2022;26:7015. 10.26355/eurrev_202210_29885
- Hajimoradi B, Hosseini B, Alirezaei T, Pourmotahari F. 25-Hydroxy vitamin D level is associated with mean platelet volume in patients with acute coronary syndrome. Cardiovasc Hematol Disord Drug Targets. 2022. 10.2174/1871529X22666220418111905
- Hoek M, Schultz M, Alummoottil S, Aneck-Hahn N, Mathabe K, et al. Ex vivo Vitamin D supplementation improves viscoelastic profiles in prostate cancer patients. Clin Hemorheol Microcirc. 2022;81:221. 10.3233/CH-211353
- Cimmino G, Conte S, Morello M, Pellegrino G, Marra L, et al. Vitamin D Inhibits IL-6 Pro-Atherothrombotic Effects in Human Endothelial Cells: A Potential Mechanism for Protection against COVID-19 Infection?. J Cardiovasc Dev Dis. 2022;9. 10.3390/jcdd9010027
- Karkouti K, Gareis M, Li C, Brandstätter H, Pichotta A, et al. Twenty years of the four-factor prothrombin complex concentrate Octaplex/Balfaxar: A narrative review. Transfus Apher Sci. 2025;64:104115. 10.1016/j.transci.2025.104115
- Valeriani E, Astorri G, Pannunzio A, Pastori D, Palumbo IM, et al. Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study. Intern Emerg Med. 2025. 10.1007/s11739-025-03922-6
- Geertsema-Hoeve BC, Radin M, Sciascia S, Urbanus RT, Huisman A, et al. Problem Solved? An Individual Ratio between Point-of-Care and Venous International Normalized Ratio Values in Two Patients with Antiphospholipid Syndrome: Two Case Reports. TH Open. 2025;9:a25425358. 10.1055/a-2542-5358
- Last J, Birschmann I, Lindau S, Konstantinides S, Grottke O, et al. Anticoagulant Management After Emergency Surgery or Major Bleeding in Anticoagulated Patients-Results of the Prospective RADOA Registry. Pharmaceuticals (Basel). 2025;18. 10.3390/ph18020170
- van de Munckhof A, van Kammen MS, Tatlisumak T, Krzywicka K, Aaron S, et al. Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study. Lancet Neurol. 2025;24:199. 10.1016/S1474-4422(24)00519-2
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. 10.36660/abc.20240147
- Hall EH, Sølsnes MH, Sandberg S, Sølvik UØ. Patient self-management of warfarin therapy - a long-term follow up study. Thromb J. 2025;23:14. 10.1186/s12959-025-00694-z
- Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. J Thromb Thrombolysis. 2025;58:165. 10.1007/s11239-025-03067-5
- Tannu M, Lopes RD, Wojdyla DM, Goodman SG, Aronson R, et al. Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS. J Am Coll Cardiol. 2025;85:1157. 10.1016/j.jacc.2024.10.125
- Zorman MJ, Vibhishanan J, Dangas K, Castle J, Li KHC, et al. Valve Thrombosis and Antithrombotic Therapy After Bioprosthetic Mitral Valve Replacement: A Systematic Review And Meta-Analysis. Eur Heart J Cardiovasc Pharmacother. 2025. 10.1093/ehjcvp/pvaf005
- Mo GL, Wen J, Ye YY, Lu YQ, Gan TM, et al. Efficacy and Safety of New Oral Anticoagulants versus Warfarin in the Resolution of Atrial Fibrillation with Left Atrial/Left Atrial Appendage Thrombus: A Systematic Review and Meta-Analysis. Rev Cardiovasc Med. 2025;26:26055. 10.31083/RCM26055
- Kempers EK, Visser C, Geijteman ECT, Goedegebuur J, Portielje JEA, et al. Discontinuation of Anticoagulants and Occurrence of Bleeding and Thromboembolic Events in Vitamin K Antagonist Users with a Life-limiting Disease. Thromb Haemost. 2025. 10.1055/a-2524-5334
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. 10.1136/openhrt-2024-002966
- Mapelli M, Celeste F, Maiolo G, Mancini E, Agostoni P. Incidental Diagnosis of Massive Mobile Left Ventricle Thrombi Following COVID-19 in a Heart Failure Patient. JACC Case Rep. 2024;29:102870. 10.1016/j.jaccas.2024.102870
- Gustafsson F, Uriel N, Netuka I, Katz JN, Pagani FD, et al. Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial. JAMA Cardiol. 2025;10:235. 10.1001/jamacardio.2024.4849
- Premkumar M, Bhujade H, Sharma P, Nain J, Ahluwalia J, et al. Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival. Aliment Pharmacol Ther. 2025;61:971. 10.1111/apt.18474
- Kim J, Kim M, Lee CS, Choi EY. Sufficient Magnesium Intake Reduces Retinal Vein Occlusion Risk: National Health and Nutrition Examination Survey Analysis. Nutrients. 2025;17. 10.3390/nu17071285
- Guo X, Zeng X, He Y, Zhang X, Shi W, et al. An Antibacterial, Antioxidant Adherent Sponge Constructed for Control of Arterial Bleeding Via Gallic Acid-Mediated Robust Assembly of Fibrous Clay in Collagen. ACS Appl Mater Interfaces. 2025;17:16489. 10.1021/acsami.4c19209
- Müller M, Ludwig L, Englert H, Riedl KA, Müller MC, et al. A novel stent flow chamber system demonstrates reduced thrombogenicity of bioresorbable magnesium scaffolds. Sci Rep. 2024;14:26691. 10.1038/s41598-024-77266-0
- Zhang J, Chen Z, Rao L, He Y. Coronary bioresorbable metallic stents: Advancements and future perspectives. J Cardiol. 2025;85:69. 10.1016/j.jjcc.2024.08.003
- Włodarczak A, Rola P, Włodarczak S, Szudrowicz M, Giniewicz K, et al. Two-Year Outcomes for Patients with Non-ST-Elevation Acute Coronary Syndrome Treated with Magmaris and Absorb Bioresorbable Scaffolds in Large-Vessel Lesions. J Pers Med. 2024;14. 10.3390/jpm14050540
- Galli S, Troiano S, Palloshi A, Rapetto C, Pisano F, et al. Comparison of acute versus stable coronary syndrome in patients treated with the Magmaris scaffold: Two-year results from the Magmaris Multicenter Italian Registry. Cardiovasc Revasc Med. 2023;57:53. 10.1016/j.carrev.2023.06.022
- Włodarczak A, Rola P, Barycki M, Furtan Ł, Łanocha M, et al. Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds - magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort. Diab Vasc Dis Res. 2023;20:14791641231188705. 10.1177/14791641231188705
- Gotru SK, Mammadova-Bach E, Sogkas G, Schuhmann MK, Schmitt K, et al. MAGT1 Deficiency Dysregulates Platelet Cation Homeostasis and Accelerates Arterial Thrombosis and Ischemic Stroke in Mice. Arterioscler Thromb Vasc Biol. 2023;43:1494. 10.1161/ATVBAHA.122.318115
- Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, et al. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study. EuroIntervention. 2023;19:e414. 10.4244/EIJ-D-23-00326
- Wlodarczak A, Montorsi P, Torzewski J, Bennett J, Starmer G, et al. One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry. EuroIntervention. 2023;19:232. 10.4244/EIJ-D-22-01069
- Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, et al. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study. EClinicalMedicine. 2023;59:101940. 10.1016/j.eclinm.2023.101940
- Pompei G, Campo G, Ruggiero R, Maffeo D, Sgura F, et al. Long-term outcomes of patients treated with sirolimus-eluting resorbable magnesium scaffolds: Insights from the SHERPA-MAGIC study. Int J Cardiol. 2023;383:1. 10.1016/j.ijcard.2023.04.029
- Fedele G, Castiglioni S, Maier JAM, Locatelli L. The Effects of Sirolimus and Magnesium on Primary Human Coronary Endothelial Cells: An In Vitro Study. Int J Mol Sci. 2023;24. 10.3390/ijms24032930
- Tonai K, Katayama S, Koyama K, Sata N, Tomioka Y, et al. Association between hypomagnesemia and coagulopathy in sepsis: a retrospective observational study. BMC Anesthesiol. 2022;22:359. 10.1186/s12871-022-01903-2
- Seguchi M, Aytekin A, Lenz T, Nicol P, Alvarez-Covarrubias HA, et al. Challenges of the newer generation of resorbable magnesium scaffolds: Lessons from failure mechanisms of the past generation. J Cardiol. 2023;81:179. 10.1016/j.jjcc.2022.09.003
- Venkatappa MM, Udagani C, Hanumegowda SM, Pramod SN, Venkataramaiah S, et al. Effect of Biofunctional Green Synthesized MgO-Nanoparticles on Oxidative-Stress-Induced Tissue Damage and Thrombosis. Molecules. 2022;27. 10.3390/molecules27165162
